Robert G. Smith, DPM, MSc, RPh, FNAP

Cover Feature

Xylazine Added to Illicit Drugs: What Podiatrists Should Know

11/01/2023

A veterinary drug, xylazine, is being found with alarming frequency as an adulterant to street drugs such as opioids and heroin. Podiatrists may uniquely encounter one of the documented adverse effects of this drug. In this feature, the...

A veterinary drug, xylazine, is...

11/01/2023

Podiatry Today

Feature

Prescribing Opioids for Pain: Exploring the CDC Clinical Practice Guidelines

07/01/2023

Robert G. Smith, DPM, MSc, RPh, FNAP

Safe and appropriate pain management is a priority in medical practice. However, guidance over the years has had to contend with problematic components. Here the author outlines newer guidelines, including an emphasis to prioritize a...

Safe and appropriate pain...

07/01/2023

Podiatry Today

Diabetes Watch

Understanding the Glucagon-like Peptide-1 Receptor Agonist Medications for Diabetes

01/01/2023

Robert G. Smith, DPM, MSc, RPh, FNAP

GLP-1 receptor agonists have many effects: helping to control appetite and blood sugar levels, facilitating the pancreas’ release of the optimal amount of insulin, which transports glucose to tissues in the body to be used for energy, and...

GLP-1 receptor agonists have...

01/01/2023

Podiatry Today

Feature

What Podiatrists Should Know About Non-Pharmacologic Options for Pain Control

09/12/2022

Robert G. Smith, DPM, MSc, RPh, FNAP

The opioid crisis, along with the continued need for quality health care, demands that providers persist in their pursuit of options to address pain as a patient concern. In this piece, the author delves into non-pharmacologic options that...

The opioid crisis, along with...

09/12/2022

Podiatry Today